These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 8381824)
41. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. Schleimer RP; Freeland HS; Peters SP; Brown KE; Derse CP J Pharmacol Exp Ther; 1989 Aug; 250(2):598-605. PubMed ID: 2547940 [TBL] [Abstract][Full Text] [Related]
42. Biosynthesis and biological activity of leukotriene B5. Terano T; Salmon JA; Moncada S Prostaglandins; 1984 Feb; 27(2):217-32. PubMed ID: 6326200 [TBL] [Abstract][Full Text] [Related]
43. Inhibition of human neutrophil leukotriene B4 synthesis by combination auranofin and eicosapentaenoic acid. James MJ; Cleland LG; Gibson RA Biochem Pharmacol; 1992 Feb; 43(4):695-700. PubMed ID: 1311589 [TBL] [Abstract][Full Text] [Related]
44. Chemotaxis of human neutrophils and eosinophils towards leukotriene B4 and its 20-w-oxidation products in vitro. Czarnetzki BM; Rosenbach T Prostaglandins; 1986 May; 31(5):851-8. PubMed ID: 3014612 [TBL] [Abstract][Full Text] [Related]
45. Effects of auranofin on leukotriene production and leukotriene stimulated neutrophil function. Hafström I; Ringertz B; Palmblad J; Malmsten C Agents Actions; 1984 Dec; 15(5-6):551-5. PubMed ID: 6099693 [TBL] [Abstract][Full Text] [Related]
46. Characterization of leukotriene B3: comparison of its biological activities with leukotriene B4 and leukotriene B5 in complement receptor enhancement, lysozyme release and chemotaxis of human neutrophils. Lee TH; Sethi T; Crea AE; Peters W; Arm JP; Horton CE; Walport MJ; Spur BW Clin Sci (Lond); 1988 May; 74(5):467-75. PubMed ID: 2836122 [TBL] [Abstract][Full Text] [Related]
47. Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1 beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals. Mølvig J; Pociot F; Worsaae H; Wogensen LD; Baek L; Christensen P; Mandrup-Poulsen T; Andersen K; Madsen P; Dyerberg J Scand J Immunol; 1991 Oct; 34(4):399-410. PubMed ID: 1656517 [TBL] [Abstract][Full Text] [Related]
48. Release of platelet-activating factor and the metabolism of leukotriene B4 by the human neutrophil when studied in a cell superfusion model. Cluzel M; Undem BJ; Chilton FH J Immunol; 1989 Dec; 143(11):3659-65. PubMed ID: 2555414 [TBL] [Abstract][Full Text] [Related]
49. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies. Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783 [TBL] [Abstract][Full Text] [Related]
50. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Goldman DW; Pickett WC; Goetzl EJ Biochem Biophys Res Commun; 1983 Nov; 117(1):282-8. PubMed ID: 6318749 [TBL] [Abstract][Full Text] [Related]
51. Dose-response effects of dietary gamma-linolenic acid-enriched oils on human polymorphonuclear-neutrophil biosynthesis of leukotriene B4. Ziboh VA; Fletcher MP Am J Clin Nutr; 1992 Jan; 55(1):39-45. PubMed ID: 1309474 [TBL] [Abstract][Full Text] [Related]
52. Effect of dietary fish oils on the formation of leukotriene B4 and B5, thromboxane and platelet activating factor by rat leukocytes. Croft KD; Codde JP; Barden A; Vandongen R; Beilin LJ Clin Exp Pharmacol Physiol; 1988 Jul; 15(7):517-25. PubMed ID: 2856061 [TBL] [Abstract][Full Text] [Related]
53. The effect of lipoproteins on the release of some eicosanoids by stimulated human leukocytes. A possible role in atherogenesis. Croft KD; Proudfoot J; Moulton C; Beilin LJ Eicosanoids; 1991; 4(2):75-81. PubMed ID: 1654959 [TBL] [Abstract][Full Text] [Related]
54. Leukotriene B5 is formed in human neutrophils after dietary supplementation with icosapentaenoic acid. Strasser T; Fischer S; Weber PC Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1540-3. PubMed ID: 2983350 [TBL] [Abstract][Full Text] [Related]
55. Enhancement of leukotriene B4 release in stimulated asthmatic neutrophils by platelet activating factor. Shindo K; Koide K; Fukumura M Thorax; 1997 Dec; 52(12):1024-9. PubMed ID: 9516893 [TBL] [Abstract][Full Text] [Related]
56. A validated liquid chromatography-mass spectrometry method for the determination of leukotrienes B4 and B5 produced by stimulated human polymorphonuclear leukocytes. Panchaud A; Avois L; Roulet M; Pilet M; Hug C; Saugy M; Decosterd LA Anal Biochem; 2005 Jun; 341(1):58-68. PubMed ID: 15866528 [TBL] [Abstract][Full Text] [Related]
57. Lipoxin A4 inhibits phosphoinositide hydrolysis in human neutrophils. Grandordy BM; Lacroix H; Mavoungou E; Krilis S; Crea AE; Spur BW; Lee TH Biochem Biophys Res Commun; 1990 Mar; 167(3):1022-9. PubMed ID: 2157419 [TBL] [Abstract][Full Text] [Related]
58. Activation of neutrophil chemotaxis by leukotriene B4 and 5-hydroxyeicosatetraenoic acid in chronic inflammatory bowel disease. Nielsen OH; Elmgreen J Scand J Clin Lab Invest; 1987 Oct; 47(6):605-11. PubMed ID: 2823370 [TBL] [Abstract][Full Text] [Related]